113 related articles for article (PubMed ID: 18974999)
1. A phase I study of combination therapy with S-1 and irinotecan (CPT-11) in patients with advanced colorectal cancer.
Shiozawa M; Sugano N; Tsuchida K; Morinaga S; Akaike M; Sugimasa Y
J Cancer Res Clin Oncol; 2009 Mar; 135(3):365-70. PubMed ID: 18974999
[TBL] [Abstract][Full Text] [Related]
2. Phase I study of S-1 combined with irinotecan (CPT-11) in patients with advanced colorectal cancer.
Tsunoda A; Yasuda N; Nakao K; Narita K; Yamazaki K; Watanabe M; Suzuki N; Kusano M
Oncology; 2007; 72(1-2):58-63. PubMed ID: 17998791
[TBL] [Abstract][Full Text] [Related]
3. Phase II study of S-1 combined with irinotecan (CPT-11) in patients with advanced colorectal cancer.
Tsunoda A; Yasuda N; Nakao K; Narita K; Watanabe M; Matsui N; Kusano M
Oncology; 2009; 77(3-4):192-6. PubMed ID: 19729976
[TBL] [Abstract][Full Text] [Related]
4. A phase I study of combination therapy with S-1 and irinotecan in patients with previously untreated metastatic or recurrent colorectal cancer.
Choi YH; Kim TW; Lee SS; Hong YS; Ryu MH; Lee JL; Chang HM; Kang YK
Cancer Chemother Pharmacol; 2011 Oct; 68(4):905-12. PubMed ID: 21290246
[TBL] [Abstract][Full Text] [Related]
5. Phase II study of combination therapy with S-1 and irinotecan in patients with advanced colorectal cancer.
Goto A; Yamada Y; Yasui H; Kato K; Hamaguchi T; Muro K; Shimada Y; Shirao K
Ann Oncol; 2006 Jun; 17(6):968-73. PubMed ID: 16603600
[TBL] [Abstract][Full Text] [Related]
6. Phase I/II study of S-1 combined with irinotecan for metastatic advanced gastric cancer.
Inokuchi M; Yamashita T; Yamada H; Kojima K; Ichikawa W; Nihei Z; Kawano T; Sugihara K
Br J Cancer; 2006 Apr; 94(8):1130-5. PubMed ID: 16570038
[TBL] [Abstract][Full Text] [Related]
7. Phase I study of S-1 combined with irinotecan (CPT-11) in patients with advanced gastric cancer (OGSG 0002).
Takiuchi H; Narahara H; Tsujinaka T; Gotoh M; Kawabe S; Katsu K; Iishi H; Tatsuta M; Fujitani K; Furukawa H; Taguchi T;
Jpn J Clin Oncol; 2005 Sep; 35(9):520-5. PubMed ID: 16141295
[TBL] [Abstract][Full Text] [Related]
8. Pilot study of simplified low-dose S-1 plus CPT-11 as first-line chemotherapy for patients with advanced colorectal cancer.
Yoshimatsu K; Yokomizo H; Fujimoto T; Umehara A; Otani T; Matsumoto A; Osawa G; Ogawa K
Anticancer Res; 2007; 27(3B):1657-61. PubMed ID: 17595792
[TBL] [Abstract][Full Text] [Related]
9. Phase I/II study of a 3-week cycle of irinotecan and S-1 in patients with advanced colorectal cancer.
Kusaba H; Esaki T; Futami K; Tanaka S; Fujishima H; Mitsugi K; Sakai K; Ariyama H; Tanaka R; Kinugawa N; Ueki T; Mibu R; Baba E; Nakano S; Akashi K
Cancer Sci; 2010 Dec; 101(12):2591-5. PubMed ID: 21077997
[TBL] [Abstract][Full Text] [Related]
10. Phase I study of bevacizumab combined with irinotecan and S-1 as second-line chemotherapy in patients with advanced colorectal cancer.
Kusaba H; Esaki T; Kishimoto J; Uchino K; Arita S; Kumagai H; Mitsugi K; Akashi K; Baba E
Cancer Chemother Pharmacol; 2013 Jan; 71(1):29-34. PubMed ID: 23228984
[TBL] [Abstract][Full Text] [Related]
11. A Phase II Trial of Combined Chemotherapy with Oral S-1 and 24-Hour Infusions of Irinotecan plus Bevacizumab in Patients with Metastatic Colorectal Cancer.
Sadahiro S; Suzuki T; Tanaka A; Okada K; Saito G; Kamijo A
Oncology; 2015; 88(6):353-9. PubMed ID: 25592116
[TBL] [Abstract][Full Text] [Related]
12. Phase I trial of weekly irinotecan combined with UFT as second-line treatment for advanced colorectal cancer.
Alonso V; Escudero P; Zorrilla M; Isla MD; Herrero A; Mayordomo JI; Martinez-Trufero J; Sáenz A; Tres A; Antón A
Eur J Cancer; 2001 Dec; 37(18):2385-91. PubMed ID: 11720832
[TBL] [Abstract][Full Text] [Related]
13. Second-line combination chemotherapy of oral S-1 with cisplatin and irinotecan for colorectal cancer resistant to 5-FU.
Tsutsumi S; Yamaguchi S; Ide M; Tsuboi K; Fukasawa T; Yamaki S; Asao T; Kuwano H
Hepatogastroenterology; 2006; 53(68):196-200. PubMed ID: 16608023
[TBL] [Abstract][Full Text] [Related]
14. [The current evidence of S-1 and irinotecan hydrochloride combination chemotherapy with tri-weekly schedule].
Goto A
Gan To Kagaku Ryoho; 2006 Jun; 33 Suppl 1():125-30. PubMed ID: 16897987
[TBL] [Abstract][Full Text] [Related]
15. Phase I/II study of CPT-11 plus UFT in patients with advanced/recurrent colorectal cancer: Osaka Gastrointestinal Cancer Chemotherapy Study Group (OGSG): Protocol 0102.
Tomita N; Fukunaga M; Okamura S; Narahara H; Uedo N; Ishihara R; Ishida H; Furukawa H; Gotoh M; Takiuchi H
Jpn J Clin Oncol; 2007 Jul; 37(7):521-7. PubMed ID: 17720738
[TBL] [Abstract][Full Text] [Related]
16. Phase I/II study of sequential therapy with irinotecan and S-1 for metastatic colorectal cancer.
Yoshioka T; Kato S; Gamoh M; Chiba N; Suzuki T; Sakayori N; Kato S; Shibata H; Shimodaira H; Otsuka K; Kakudo Y; Takahashi S; Ishioka C
Br J Cancer; 2009 Dec; 101(12):1972-7. PubMed ID: 19920821
[TBL] [Abstract][Full Text] [Related]
17. A phase II study of combination therapy with irinotecan and S-1 (IRIS) in patients with advanced colorectal cancer.
Shiozawa M; Akaike M; Sugano N; Tsuchida K; Yamamoto N; Morinaga S
Cancer Chemother Pharmacol; 2010 Oct; 66(5):987-92. PubMed ID: 20623226
[TBL] [Abstract][Full Text] [Related]
18. Combination chemotherapy of biweekly irinotecan (CPT-11) plus tegafur/uracil (UFT) and leucovorin (LV) for patients with metastatic colorectal cancer: phase I/II study in Japanese patients.
Okabayashi K; Hasegawa H; Ishii Y; Endo T; Ochiai H; Kubota T; Kitagawa Y
Cancer Chemother Pharmacol; 2009 Feb; 63(3):501-7. PubMed ID: 18461329
[TBL] [Abstract][Full Text] [Related]
19. Phase I/II trial of irinotecan and S-1 combination chemotherapy as a second-line treatment for advanced colorectal cancer.
Takii Y; Yamazaki T; Okada T; Tani T; Funakoshi K; Maruyama S; Hasegawa J; Akazawa K; Hatakeyama K;
Chemotherapy; 2013; 59(5):338-43. PubMed ID: 24820531
[TBL] [Abstract][Full Text] [Related]
20. Phase I clinical and pharmacokinetic/pharmacogenetic study of a triplet regimen of S-1/irinotecan/oxaliplatin in patients with metastatic colorectal or gastric cancer.
Park SR; Hong YS; Lim HS; Seong MW; Kong SY; Kim SY; Park YI; Jung KH
Cancer Chemother Pharmacol; 2013 Nov; 72(5):953-64. PubMed ID: 23982118
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
